S100A9诱导的PD-1/PD-L1过表达导致骨髓增生异常综合征无效造血
该研究探讨PD-1/PD-L1免疫检查点在MDS无效造血中的作用。发现MDS患者HSPC上PD-1及MDSC上PD-L1表达较健康供者增加,S100A9可诱导该检查点激活,PD-1/PD-L1阻断可恢复MDS患者骨髓单个核细胞的有效造血和集落形成能力,c-Myc参与S100A9诱导的PD-1/PD-L1上调。
要点
- MDS患者HSPC上PD-1及MDSC上PD-L1表达较健康供者增加
- S100A9可诱导PD-1/PD-L1检查点激活,重组PD-L1处理MDS骨髓单个核细胞可致细胞死亡
- PD-1/PD-L1阻断可恢复MDS患者骨髓单个核细胞的有效造血和集落形成能力
核心结论
- 抗PD-1/抗PD-L1阻断策略在恢复MDS有效造血方面具有治疗前景。
研究设计与样本
- 研究比较了MDS患者与健康供者的HSPC和MDSC上PD-1/PD-L1表达,并使用了S100A9转基因小鼠及MDS患者骨髓单个核细胞进行体外实验。
主要发现
- MDS患者HSPC上PD-1及MDSC上PD-L1表达较健康供者增加,该检查点在S100A9转基因小鼠及S100A9处理的骨髓单个核细胞中也被激活。
- 重组PD-L1处理MDS骨髓单个核细胞可导致细胞死亡,提示PD-1/PD-L1相互作用参与MDS中HSPC死亡。
- PD-1/PD-L1阻断可恢复MDS患者骨髓单个核细胞的有效造血并改善集落形成能力,在老龄S100A9转基因小鼠中观察到相似结果。
- c-Myc是S100A9诱导PD-1/PD-L1上调所必需的,抗PD-1抗体处理MDS HSPC可抑制Myc靶基因表达并增加造血通路基因表达。
临床怎么用
- 作者认为抗PD-1/抗PD-L1阻断策略在恢复MDS有效造血方面具有治疗前景。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) are characterized by dysplastic and ineffective hematopoiesis that can result from aberrant expansion and activation of myeloid-derived suppressor cells (MDSCs) within the bone marrow (BM) niche. MDSCs produce S100A9, which mediates premature death of hematopoietic stem and progenitor cells (HSPCs). The PD-1/PD-L1 immune checkpoint impairs immune responses by inducing T-cell exhaustion and apoptosis, but its role in MDS is uncharacterized. Here we report an increased expression of PD-1 on HSPCs and PD-L1 on MDSCs in MDS versus healthy donors, and that this checkpoint is also activated in S100A9 transgenic (S100A9Tg) mice, and by treatment of BM mononuclear cells (BM-MNC) with S100A9. Further, MDS BM-MNC treated with recombinant PD-L1 underwent cell death, suggesting that the PD-1/PD-L1 interaction contributes to HSPC death in MDS. In accordance with this notion, PD-1/PD-L1 blockade restores effective hematopoiesis and improves colony-forming capacity in BM-MNC from MDS patients. Similar findings were observed in aged S100A9Tg mice. Finally, we demonstrate that c-Myc is required for S100A9-induced upregulation of PD-1/PD-L1, and that treatment of MDS HSPCs with anti-PD-1 antibody suppresses the expression of Myc target genes and increases the expression of hematopoietic pathway genes. We conclude anti-PD-1/anti-PD-L1 blocking strategies offer therapeutic promise in MDS in restoring effective hematopoiesis.
引用
- Cheng P, Eksioglu EA, Chen X, et al. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Leukemia. 2019. PMID: 30737486. doi:10.1038/s41375-019-0397-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。